KFC Plans Major Investment in UK and Ireland

Published 2 hours agoYUM

KFC Plans Major Investment in UK and Ireland

KFC has unveiled a substantial £1.49 billion ($2 billion) investment strategy for the UK and Ireland over the next five years, with the creation of over 7,000 jobs at the core of its plan. This initiative reflects KFC's commitment to expand its foothold in these regions significantly.

The fast-food giant aims to open 500 additional outlets over the next decade. The move is not just about expansion; it's a response to the thriving demand for fried chicken, a market estimated at £3.1 billion in the UK. Reuters reported that the growing consumer preference for fried chicken is outpacing other quick-service restaurant categories, creating a ripe environment for KFC's ambitious growth.

In a recent move to consolidate its market presence, KFC purchased 218 restaurants from its largest franchisee in the UK and Ireland, EG Group, in December 2023. The acquisition, expected to finalize by mid-2024, exemplifies KFC's strategy to strengthen its market position, although it is anticipated to have little impact on Yum! Brands' financial results for 2024, according to the Irish Times.

Share this article

Twitter Facebook LinkedIn

Recent Articles

AutoZone Reports Rising Sales but Misses Profit Expectations

AutoZone Reports Rising Sales but Misses Profit Expectations

13 minutes agoAZO

AutoZone's fiscal third-quarter report highlighted a rise in net sales to $4.235 billion, reflecting a 3.5% increase compared to the same period last year. However, the company's net income did not meet market expectations, coming in at $795.8 million despite a 1.5% increase from the previous year. The same-store sales numbers showed a marginal total company increase of 0.9%, with domestic figures remaining flat, according to the company's own reports. Supporting details from the financial breakdown reveal that AutoZone's earnings per share (EPS) saw a 4.5% boost, reaching $36.69 year-over-year. Gross profit also climbed to $2.266 billion, up 5.6%. On the expense side, however, operating costs grew by 6.0% to $1.365 billion. Notably, interest expenses jumped significantly to $104.4 million from $74.3 million in the previous year, which contributed to the profit shortfall. The results indicate that while sales efforts are effective, cost management presents a challenge for AutoZone. The company faces increasing operational and interest expenses, coupled with a higher income tax expense of $144.0 million compared to last year's $136.4 million. Reuters noted the company's ongoing struggle to balance sales growth with managing expenses effectively.

Gilat Secures Over $25 Million in Orders for Satellite Solutions

Gilat Secures Over $25 Million in Orders for Satellite Solutions

28 minutes agoGILT

Gilat Satellite Networks recently announced securing over $25 million in new orders for its multi-orbit satellite solutions. These contracts signal substantial growth in demand for Gilat's technology across a range of applications. In January 2025, the company received $9 million in orders from major satellite operators for its advanced SkyEdge IV and SkyEdge II-c platforms, with deliveries expected within a year. In April 2025, Gilat further strengthened its position with over $15 million in orders from leading global satellite operators. These latest contracts, to be delivered throughout the year, focus on multi-service uses, especially in In-Flight Connectivity across GEO, MEO, and LEO Very High Throughput Satellite constellations. Earlier, in April 2024, Gilat's U.S. subsidiary, DataPath, was awarded a $12 million contract to supply the U.S. Army with satellite connectivity enhancements, as reported by Satellite Today. Additionally, April 2024 saw contracts totaling $13 million with various satellite operators to expand their networks using Gilat's SkyEdge IV capabilities. These ongoing developments indicate Gilat's continuing prominence in both commercial and defense sectors, showcasing the company's multi-orbit satellite technology and commitment to global communication solutions.

Rocket Pharmaceuticals Faces Setback with FDA Trial Hold

Rocket Pharmaceuticals Faces Setback with FDA Trial Hold

43 minutes agoRCKT

Rocket Pharmaceuticals recently faced a significant setback when the FDA imposed a hold on its mid-stage clinical trial following the death of a trial participant. This pause is meant to give time for a comprehensive investigation into the unfortunate incident. The impact of this development was immediately reflected in the company's stock, which saw a notable decline. Investors reacted swiftly to the news, reflecting concerns over the suspension and the potential delays it could cause in the company's efforts to advance its treatments. Rocket Pharmaceuticals has stated that it is working closely with the FDA to address the issues that have arisen and is focused on resuming the trial as soon as possible. This event is not isolated, as similar holds have been placed in the past on trials from companies like Juno Therapeutics and Rapt Therapeutics, as reported by sources such as FierceBiotech and Reuters.

AstraZeneca's Imfinzi Advances in Global Bladder Cancer Treatments

AstraZeneca's Imfinzi Advances in Global Bladder Cancer Treatments

58 minutes agoAZN

AstraZeneca's immunotherapy drug, Imfinzi (durvalumab), is making strides in the treatment of muscle-invasive bladder cancer (MIBC). The company has recently submitted an application to the European Medicines Agency (EMA) for its use based on positive results from the NIAGARA Phase III trial. This trial demonstrated a significant 32% reduction in the risk of disease progression or recurrence and a 25% reduction in the risk of death compared to standard mechanisms, as reported by Europawire. In the United States, Imfinzi has already received approval from the U.S. Food and Drug Administration (FDA) as of March 2025. The FDA approved its use in combination with gemcitabine and cisplatin as a neoadjuvant treatment, followed by Imfinzi monotherapy, for adults with MIBC undergoing radical cystectomy. The approval was also based on the outcomes from the NIAGARA trial, according to Biospace. Efforts to expand the use of Imfinzi in treating MIBC are ongoing globally, with regulatory applications currently under review in several countries, including Japan and Brazil. These developments emphasize AstraZeneca's strategy to establish Imfinzi as a primary treatment option worldwide for this aggressive cancer type.